New hope for lymphoma patients: stem cell combo targets brain relapse

NCT ID NCT07481669

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Mar 23, 2026 · Last updated May 23, 2026 · Updated 9 times

Summary

This study tests a modified chemotherapy regimen (TEAM) followed by a stem cell transplant for lymphoma patients at high risk of the cancer spreading to the brain or spinal cord. The goal is to see if this approach can help patients stay cancer-free longer with fewer side effects than standard treatments. About 45 adults aged 18-70 who have already responded to initial therapy will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA PATIENTS WITH HIGH-RISK OF CENTRAL NERVOUS SYSTEM RELAPSE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
RECRUITING

Hangzhou, Zhejiang, 310000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LYMPHOMA PATIENTS WITH HIGH-RISK OF CENTRAL NERVOUS SYSTEM RELAPSE